Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Guzel, Mukhametshina"'
Autor:
Roy S. Herbst, Yi-Long Wu, Thomas John, Christian Grohe, Margarita Majem, Jie Wang, Terufumi Kato, Jonathan W. Goldman, Konstantin Laktionov, Sang-We Kim, Chong-Jen Yu, Huu Vinh Vu, Shun Lu, Kye Young Lee, Guzel Mukhametshina, Charuwan Akewanlop, Filippo de Marinis, Laura Bonanno, Manuel Domine, Frances A. Shepherd, Damien Urban, Xiangning Huang, Ana Bolanos, Marta Stachowiak, Masahiro Tsuboi
Publikováno v:
Journal of Clinical Oncology. 41:1830-1840
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e4209c2a30ea8588f1e79771f3c93f7
https://doi.org/10.1200/jco.22.02186
https://doi.org/10.1200/jco.22.02186
Autor:
Alexey Manikhas, Hans Friedrich Koch, Charuwan Akewanlop, Kakhaber Baramidze, Sirshendu Roy, Gopichand Mamillapalli, Ashwani Marwah, Virote Sriuranpong, Eduardo Yanez Ruiz, Miguel Hernandez-Bronchud, Unmesh Gopalakrishnan, Maria Luisa T. Abesamis-Tiambeng, Guzel Mukhametshina, Abhijit Barve, Joseph D. Parra, Adolfo Fuentes-Alburo, Ihor Vynnychenko, Sarika Deodhar, Gia Nemsadze, Igor Bondarenko, Eduardo J. Pennella, Cornelius F. Waller, Hope S. Rugo, Jay Herson, Subramanian Loganathan
Publikováno v:
Breast Cancer Research and Treatment
Breast cancer research and treatment, vol 188, iss 2
Breast cancer research and treatment, vol 188, iss 2
Purpose The phase 3 HERITAGE trial demonstrated that the biosimilar trastuzumab-dkst is well tolerated with similar efficacy (measured by overall response rate [ORR] and progression-free survival [PFS]) compared with originator trastuzumab combined w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d96d7db24623d3a61483158ddd9eb8f3
https://doi.org/10.1007/s10549-021-06197-5
https://doi.org/10.1007/s10549-021-06197-5
Autor:
M. Yu. Fedyanin, L. A. Zagorskaya, O. L. Fakhrutdinova, O. V. Nekrasova, S. A. Belukhin, A. A. Mishchenko, L. Yu. Vladimirova, Alfia Khasanova, B. Kh. Kertiev, Ye. V. Karabina, A. K. Ivanova, A. V. Belyayeva, Viacheslav Chubenko, A. V. Androsova, Alexey Tryakin, P S Feoktistova, Rashida Orlova, Guzel Mukhametshina, S. N. Osodoyeva, R. R. Malina, I. A. Pokatayev, O. Yu. Novikova, L. V. Khalikova, V. M. Sherstnev, A. A. Meshcheryakov, Sanal Erdniev, Elena Artamonova, Kh. S. Musayeva, Irina L. Popova, L. A. Mukova, Larisa Bolotina, F. V. Moiseyenko, A. I. Katz, Ye. S. Kuzmina, G. I. Kosar, I. Yu. Stradayeva, Vladimir Moiseyenko, S. A. Tyulyandin, A S Zhabina, A. Belonogov
Publikováno v:
Malignant tumours. 9:53-63
Purpose. To assess the incidence and severity of adverse events; to explore clinical factors associated with grade 3–4 non-hematologic toxicity; to assess the immediate efficacy and progression-free survival during treatment with the FOLFIRI regime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9613a093c5463524ababf46a1ed45eff
https://doi.org/10.18027/2224-5057-0-0-0-
https://doi.org/10.18027/2224-5057-0-0-0-
Autor:
Christoph Hoeller, Marie-Francoise Avril, Pietro Quaglino, François Aubin, Lars Bastholt, Takashi Inozume, Virginia Ferraresi, Michael B. Jameson, Kevin B. Kim, Oliver Bechter, Dirk Schadendorf, Kenji Yokota, Carmen Loquai, Maria-Jose Passos, Inge Marie Svane, Michele Maio, Catherine Barrow, Frank Meiss, Nageatte Ibrahim, Andrzej Mackiewicz, Phillip Parente, Tatsuya Takenouchi, Caroline Dutriaux, Piotr Rutkowski, Alfonsus J M van den Eertwegh, Paola Queirolo, Catriona M. McNeil, Peter Mohr, Felix Kiecker, Susana Puig, Friedegund Meier, Lutz Kretschmer, Alexander C.J. van Akkooi, Alex Menzies, Timothy Crook, Christian U. Blank, Suzana Matkovic, Michael C. Brown, Ragini R. Kudchadkar, Max Levin, Rüdiger Hein, Tanja Skytta, Gerald P. Linette, Clemens Krepler, Adnan Khattak, Ernest Marshall, Joseph Kerger, Oddbjorn Straume, Laurent Mortier, Jochen Utikal, Micaela Hernberg, James Larkin, Yoshio Kiyohara, Mario Mandalà, Henrik Schmidt, Daniil Stroyakovskiy, Pablo Luis Ortiz Romero, Naoya Yamazaki, John Walker, Anna Maria Di Giacomo, Lionel Geoffrois, Jean-Philippe Lacour, Caroline Robert, Vincent Descamps, Shahneen Sandhu, Gil Bar-Sela, Paul C. Nathan, Marcin Dzienis, Ralf Gutzmer, Claus Garbe, Andrey Meshcheryakov, Patrick Combemale, Martin Fehr, Guzel Mukhametshina, Helena Kapiteijn, Geke A. P. Hospers, Jun Aoi, Andrew Haydon, Rutger H. T. Koornstra, Marie-Thérèse Leccia, Sigrun Hallmeyer, Pier Francesco Ferrucci, Jean-Jacques Grob, Leonel Hernandez-Aya, Jan-Christoph Simon, Vanna Chiarion Sileni, Alain Algazi, Lidija Sekulovic, Sandrine Marreaud, Bernard Fitzharris, Jacob Schachter, Xinni Song, Wolf-Henning Boehncke, Rahima Jamal, Paul Lorigan, Maureen J.B. Aarts, Reinhard Dummer, Mike McCrystal, César Martins, Reiner Hofmann-Wellenhof, Alexander M.M. Eggermont, Carola Berking, Elaine Dunwoodie, Bernard Guillot, Michal Kicinski, Philippe Saiag, Céleste Lebbé, Thierry Lesimple, Stefan Suciu, Michal Lotem, Paula Ferreira, Mohammed M. Milhem, Laurent Machet, Patrick Terheyden, Anna Katharina Winge-Main, Peter Hersey, Jean-Francois Baurain, Axel Hauschild, Stéphane Dalle, Jean-Philippe Arnault, Paolo A. Ascierto, Gerard Groenewegen, Florent Grange, Georgina V. Long, Victoria Atkinson, Philippa Corrie, Matteo S. Carlino, Thomas Jouary, Daniel Hendler, Richard Casasola, Ashita Waterston, Jessica C. Hassel
Publikováno v:
EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 643-654 . https://doi.org/10.1016/S1470-2045(21)00065-6
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Group
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Group
Background: The European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. At 15-month median follow-up, pembrolizumab improv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca46af8de45fdf5ffd9d70f717e94208
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027
Autor:
Karen A. Gelmon, Peter A. Fasching, Fergus J. Couch, Judith Balmaña, Suzette Delaloge, Intidhar Labidi-Galy, James Bennett, Susan McCutcheon, Graham Walker, Joyce O'Shaughnessy, Constanta Timcheva, Antoaneta Tomova, Andrea Eisen, Karen Gelmon, Julie Lemieux, Fernando Bazan, Hugues Bourgeois, Camille Chakiba, Mohamad Chehimi, Florence Dalenc, Thibault De La Motte Rouge, Jean-Sébastien Frenel, Anthony Gonçalves, Anne Claire Hardy-Bessard, Regine Lamy, Christelle Levy, Alain Lortholary, Audrey Mailliez, Jacques Medioni, Anne Patsouris, Dominique Spaeth, Luis Teixeira, Isabelle Tennevet, Cristian Villanueva, Benoit You, Johannes Ettl, Bernd Gerber, Oliver Hoffmann, Tjoung-Won Park-Simon, Mattea Reinisch, Joke Tio, Pauline Wimberger, Katalin Boer, Alberto Ballestrero, Giampaolo Bianchini, Laura Biganzoli, Roberto Bordonaro, Francesco Cognetti, Michelino De Laurentiis, Sabino De Placido, Valentina Guarneri, Filippo Montemurro, Giuseppe Naso, Armando Santoro, Claudio Zamagni, Seung-Jin Kim, Seigo Nakamura, Yee Soo Chae, Eun Kyung Cho, Kim Jee Hyun, Seock-Ah Im, Keun Seok Lee, Yeon Hee Park, Joo Hyuk Sohn, Tomasz Byrski, Tomasz Huzarski, Bozena Kukielka-Budny, Zbigniew Nowecki, Renata Szoszkiewicz, Rafal Tarnawski, Viktoria Dvornichenko, Fedor Moiseenko, Guzel Mukhametshina, Elena Poddubskaya, Ekaterina Popova, Anna Tarasova, Anna Vats, Bárbara Adamo, Raquel Andrés Conejero, Antonio Antón Torres, Judith Balmaña Gelpi, Nieves Díaz Fernández, Alejandro Falcón González, Juan Garcia, Isabel Lorenzo-Lorenzo, Fernando Moreno Antón, Marta Santisteban, Agostina Stradella, Chiun-Sheng Huang, Sercan Aksoy, Cagatay Arslan, Mehmet Artac, Adnan Aydiner, Ozgur Ozyilkan, Emel Sezer, Anne Armstrong, Sophie Barrett, Annabel Borley, Zoe Kemp, Caroline Michie, Mukesh Mukesh, Timothy Perren, Angela Swampillai, Tammy Young
Publikováno v:
European journal of cancer (Oxford, England : 1990). 152
Background In the phase III OlympiAD trial, olaparib significantly increased progression-free survival (PFS) compared with chemotherapy of physician's choice in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor 2 (HER2)-nega
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf39309b7bb719fd0c3675e31c646e0c
https://pubmed.ncbi.nlm.nih.gov/34087573
https://pubmed.ncbi.nlm.nih.gov/34087573
Autor:
I. Stradaeva, Fedor Moiseenko, V. Chubenko, O. Novikova, A. Popova, Rashida Orlova, Anna V. Kudryavtseva, I. Popova, S. Beluhin, A S Zhabina, Evgeniya Kuzmina, A. Micshenko, M. Lyadova, Mikhail Fedyanin, A. Belonogov, H. Musaeva, Guzel Mukhametshina, A. Khasanova, Larisa Bolotina, Liubov Yu Vladimirova, B. Kertiev, S. A. Tjulandin
Publikováno v:
Annals of Oncology. 31:S184-S185
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40e2ff8f8855d34eb74698f7968c954d
https://doi.org/10.1016/j.annonc.2020.04.373
https://doi.org/10.1016/j.annonc.2020.04.373
Autor:
S V Limareva, Irina V. Evstigneeva, A. E. Storozhakova, E P Prokofyeva, Elena Karabina, L V Manziuk, Irina L. Popova, N Yu Samaneva, Natalya A Abramova, Elena A. Kalabanova, Natalya Mikhailovna Tikhanovskaya, Viacheslav Chubenko, Larisa Bolotina, I. S. Mitashok, L Yu Vladimirova, I I Andreyashkina, Elena Kovalenko, Vera Gorbunova, Guzel Mukhametshina, Alfia Khasanova, Ya. V. Svetitskaya, A A Teterich, E A Gaysina, T A Snezhko
Publikováno v:
Современная онкология, Vol 18, Iss 3, Pp 27-32 (2016)
The article shows the experience of eribulin application in actual clinical practice in Oncology institutions of the Russian Federation concerning metastatic breast cancer. We have analyzed the efficacy of the drug in case of different subtypes of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fa75504345f75181bf935130bbd9f72
https://modernonco.orscience.ru/1815-1434/article/viewFile/27073/pdf
https://modernonco.orscience.ru/1815-1434/article/viewFile/27073/pdf
Autor:
Alexey Manikhas, N. Popova, T. Karandeeva, A. Safarova, I. Evstigneeva, Larisa Bolotina, Guzel Mukhametshina, Irina V. Kolyadina, A. Khasanova, Dmitry Ponomarenko, Elena Kovalenko, R. Ekaterina, Elena Karabina, L. Kramskaya, Ludmila Manzyuk, I. Shumskaya, I. Suslova, M. Volkonsky, Larisa Zhilyaeva, Vera Gorbunova
Publikováno v:
European Journal of Cancer. 138:S59
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::242c7a41dbceb73647084b375877da34
https://doi.org/10.1016/s0959-8049(20)30684-5
https://doi.org/10.1016/s0959-8049(20)30684-5
Autor:
Thomas Bachelot, Alberto Ballestrero, Marco Colleoni, José Valero Alvarez, Amer Sami, Celalettin Camci, Rodrigo Lastra del Prado, Luis De La Cruz Merino, Antonio Bernardo, Peter Barrett-Lee, Yolanda Fernández Pérez, Vladimir Semiglazov, Thierry Petit, Mette Holck Nielsen, C. Langridge, Guillermo López Vivanco, Nik Hauser, Ignacio Porras Quintela, José Manuel Pérez García, Anna-Karin Wennstig, Victoria Dvornichenko, Erik Jakobsen, Guzel Mukhametshina, Heiko Graf, V. Jenkins, Mireille Mousseau, Alfonso Sanchez Muñoz, Pehr Lind, Irina Bulavina, Alexey Manikhas, Bengt Norberg, Xavier Pivot, Per Edlund, Sandeep Sehdev, Valerie Jenkins, Santos Enrech Frances, Nadia Califaretti, V. Müller, G. Curigliano, Duncan Wheatley, Stephen L. Chan, Enrique Espinosa Arranz, S. Osborne, Soeren Linnet, Nana Scotto, J. Gligorov, Volkmar Müller, Tjoung-Won Park-Simon, Karen McAdam, Ann Knoop, Giuseppe Curigliano, X. Pivot, Justine Kilkerr, Georg Heinrich, L. Fallowfield, Francisco Carabantes Ocon, Christopher Wolf, Robert El-Maraghi, Hugues Bourgeois, Christelle Levy, Luca Gianni, Russell Burcombe, Vadim Shirinkin, Huseyin Abali, Etienne Brain, Christoph Tausch, Lidia Perlova-Griff, Claudia Plesse Lefeuvre, Joseph Gligorov, Mikhail Lichinitser, Friedrich Overkamp, S. Verma, Kathryn Monson, Angela Stefania Ribecco, Doris Augustin, Lesley Fallowfield, Saad Tahir, Javier Cassinello Espinosa, Marcus Schmidt, Jacek Jassem, Laurent Zelek, Ruchan Uslu, Richard Simcock, Sherko Kuemmel, Javier Salvador Bofill, A. Knoop, Hervé Bonnefoi, Fikret Arpaci, Silvana Spadafora, Sunil Verma, Hendrik Kroening, Elżbieta Brewczynska
Publikováno v:
Annals of Oncology. 25:1979-1987
Patients with HER2-positive early breast cancer (EBC) preferred subcutaneous (s.c.) trastuzumab, delivered via single-use injection device (SID), over the intravenous (i.v.) formulation (Cohort 1 of the PrefHer study: NCT01401166). Here, we report pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b145cdce1456ae985a553171af8850a2
https://doi.org/10.1093/annonc/mdu364
https://doi.org/10.1093/annonc/mdu364
Autor:
Ihor Vynnychenko, Virote Sriuranpong, Jinyu Yuan, Jay Herson, Eduardo Yanez Ruiz, Guzel Mukhametshina, Hope S. Rugo, Gia Nemsadze, Alexey Manikhas, Eduardo J. Pennella, Sirshendu Ray, Gopichand Mamillapalli, Igor Bondarenko, Kakhaber Baramidze, Charuwan Akewanlop, Mudgal Kothekar, Mark Baczkowski, Joseph D. Parra, Rajiv Sharma, Subramanian Loganathan, Miguel Hernandez-Bronchud, Cornelius F. Waller, Maria Luisa T. Abesamis-Tiambeng, Abhijit Barve
Publikováno v:
JAMA. 317(1)
Importance Treatment with the anti-ERBB2 humanized monoclonal antibody trastuzumab and chemotherapy significantly improves outcome in patients with ERBB2 (HER2)–positive metastatic breast cancer; a clinically effective biosimilar may help increase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90def91ec46cab4075076390dc4ef2a0
https://pubmed.ncbi.nlm.nih.gov/27918795
https://pubmed.ncbi.nlm.nih.gov/27918795